Vaccine vectors and methods of enhancing immune responses
Provided herein are vaccine vectors including an antigenic polypeptide and an HMGB1 polypeptide present on the surface of the vaccine vector. Compositions comprising the vaccine vectors are also provided and include a pharmaceutically acceptable carrier, suitably a carrier for oral or nasal administration. Also provided are methods of enhancing immune responses, in particular antibody immune response and suitably an IgA response, by administering the vaccine vectors or compositions disclosed herein to a subject.
1. A vaccine vector comprising a first polynucleotide sequence encoding an antigenic polypeptide and a second polynucleotide sequence encoding an immunostimulatory polypeptide, wherein the vaccine vector is a bacterial vaccine vector, wherein the immunostimulatory polypeptide is an HMGB1 polypeptide, and wherein the antigenic polypeptide and the HMGB1 polypeptide are present on the surface of the vaccine vector.
2. The vaccine vector of claim 1 , wherein the antigenic polypeptide is an Influenza specific polypeptide.
3. The vaccine vector of claim 2 , wherein the antigenic polypeptide is an M2e, HA or NP Influenza polypeptide.
4. The vaccine vector of claim 3 , wherein the antigenic polypeptide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, an immunogenic fragment of SEQ ID NO:1, an immunogenic fragment of SEQ ID NO:2, an immunogenic fragment of SEQ ID NO:3, an immunogenic fragment of SEQ ID NO:4, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, an immunogenic fragment of SEQ ID NO: 7, an immunogenic fragment of SEQ ID NO: 8, an immunogenic fragment of SEQ ID NO: 9, and an immunogenic fragment of SEQ ID NO: 10.
5. The vaccine vector of claim 1 , wherein the HMGB1 polypeptide is selected from SEQ ID NO: 18, SEQ ID NO: 29 and SEQ ID NO: 30.
6. The vaccine vector of claim 1 , wherein the bacterial vaccine vector is a Bacillus spp.
7. The vaccine vector of claim 1 , wherein the antigenic polypeptide and the HMGB1 polypeptide are linked in frame.
8. A composition comprising the vaccine vector of claim 1 and a pharmaceutically acceptable carrier.
9. The composition of claim 8 , wherein the pharmaceutically acceptable carrier is acceptable for oral or nasal administration.
10. The composition of claim 8 , wherein the vaccine vector is not capable of replication or is inactivated or killed.
11. A method of inducing an immune response in a subject comprising administering to the subject the vaccine vector of claim 1 in an amount effective to induce the immune response of the subject to the antigenic polypeptide.
12. The method of claim 11 , wherein the vaccine vector is administered orally or intranasally.
13. The method of claim 12 , wherein the immune response is an IgA antibody response to the antigenic polypeptide.
14. The method of claim 11 , wherein the vaccine vector is not capable of replication in the subject or is inactivated or killed prior to administration to the subject.
15. A vaccine vector comprising a first polynucleotide sequence encoding an antigenic polypeptide present on the surface of the vaccine vector and a second polynucleotide sequence encoding an immunostimulatory polypeptide, wherein the vaccine vector is a Bacillus spp. and wherein the antigenic polypeptide and the immunostimulatory polypeptide are present on the surface of the vaccine vector, wherein the antigenic polypeptide is an Influenza polypeptide and wherein the immunostimulatory polypeptide is a HMGB1 polypeptide.
16. The vaccine vector of claim 15 , wherein the first polynucleotide and the second polynucleotide are inserted within a third polynucleotide sequence encoding an external portion of a transmembrane protein of the Bacillus spp.
17. The vaccine vector of claim 15 , wherein the antigenic polypeptide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, an immunogenic fragment of SEQ ID NO:1, an immunogenic fragment of SEQ ID NO:2, an immunogenic fragment of SEQ ID NO:3, an immunogenic fragment of SEQ ID NO:4, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10.
18. The vaccine vector of claim 15 , wherein the HMGB1 polypeptide is selected from SEQ ID NO: 18, SEQ ID NO: 29 and SEQ ID NO: 30.
19. A method of inducing an immune response in a subject comprising administering to the subject the vaccine vector of claim 15 in an amount effective to induce the immune response of the subject to the Influenza polypeptide.
20. The method of claim 19 , wherein the vaccine vector is administered orally or intranasally.
21. The method of claim 20 , wherein the immune response is an IgA antibody response to the antigenic polypeptide.
22. The method of claim 19 , wherein the vaccine vector is not capable of replication in the subject or is inactivated or killed prior to administration to the subject.
23. The vaccine vector of claim 15 , further comprising a CD154 polypeptide comprising amino acids 140-149 of SEQ ID NO: 12.
24. The vaccine vector of claim 1 , wherein the antigenic polypeptide and the HMGB1 polypeptide are expressed within an external loop of an transmembrane protein of the bacterial vaccine vector.